Skip to Main Content

Paper Details

A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.
Leukemia
1
2023
Author NameAffiliation
Svitlana TyekuchevaDana-Farber Cancer Institute
  • 1 - 1

Datasets

Release 1.2